Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.43 |
| ▸ | BMPR1B | O00238 | 3/20 | 0.43 |
| ▸ | BMPR1A | P36894 | 3/20 | 0.43 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 3/20 | 0.41 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29443963 | 1.00 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2BMAPK14 | |
| SCHEMBL4584161 | 0.91 | ADORA2A (0.84) | ADORA2AADORA1ADORA3ADORA2BMAPK14 | |
| SCHEMBL4586085 | 0.88 | ADORA2A (0.79) | ADORA2AADORA1ADORA3ADORA2BTGFBR1 | |
| SCHEMBL4584666 | 0.87 | ADORA2A (0.77) | ADORA2AADORA1ADORA3ADORA2BMAPK14 | |
| SCHEMBL4584024 | 0.87 | ADORA2A (0.77) | ADORA2AADORA1TGFBR1BMPR1BBMPR1A | |
| SCHEMBL4584767 | 0.87 | ADORA2A (0.77) | ADORA2AADORA1ADORA3ADORA2BTGFBR1 | |
| SCHEMBL4585498 | 0.86 | ADORA2A (0.76) | ADORA2AADORA1ADORA3ADORA2BTGFBR1 | |
| SCHEMBL4584522 | 0.86 | ADORA2A (0.75) | ADORA2AADORA1ADORA3ADORA2BMAPK14 | |
| SCHEMBL4584525 | 0.86 | ADORA2A (0.75) | ADORA2AADORA1ADORA3ADORA2BMAPK14 | |
| SCHEMBL4585799 | 0.86 | ADORA2A (0.75) | ADORA2AADORA1ADORA3ADORA2BNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114053269-A | Adenosine A1/A2ADual receptor antagonists | 南开大学 | 2022-02-18 | — | — | CN | disclosed |
| EP-2838530-B1 | METHODS FOR TREATING PARKINSON'S DISEASE | UCB BIOPHARMA SPRL (BE) | 2017-04-05 | — | — | EP | disclosed |
| EP-2838530-B1 | METHODS FOR TREATING PARKINSON'S DISEASE | UCB BIOPHARMA SPRL (BE) | 2017-04-05 | — | — | EP | disclosed |
| US-20160367560-A1 | Methods for Treating Parkinson's Disease | UCB PHARMA, S.A. (BE) | 2016-12-22 | — | — | US | disclosed |
| US-20160367560-A1 | Methods for Treating Parkinson's Disease | UCB PHARMA, S.A. (BE) | 2016-12-22 | — | — | US | disclosed |
| US-20160367560-A1 | Methods for Treating Parkinson's Disease | UCB PHARMA, S.A. (BE) | 2016-12-22 | — | — | US | disclosed |
| US-9387212-B2 | Methods for treating Parkinson's disease | UCB BIOPHARMA SPRL (BE) | 2016-07-12 | — | — | US | disclosed |
| US-9387212-B2 | Methods for treating Parkinson's disease | UCB BIOPHARMA SPRL (BE) | 2016-07-12 | — | — | US | disclosed |
| US-9387212-B2 | Methods for treating Parkinson's disease | UCB BIOPHARMA SPRL (BE) | 2016-07-12 | — | — | US | disclosed |
| US-20150157638-A1 | Methods for Treating Parkinson's Disease | UCB BIOPHARMA SPRL (BE) | 2015-06-11 | — | — | US | disclosed |
| US-20150157638-A1 | Methods for Treating Parkinson's Disease | UCB BIOPHARMA SPRL (BE) | 2015-06-11 | — | — | US | disclosed |
| US-20150157638-A1 | Methods for Treating Parkinson's Disease | UCB BIOPHARMA SPRL (BE) | 2015-06-11 | — | — | US | disclosed |
| US-7407961-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2008-08-05 | — | — | US | disclosed |
| US-20050113387-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113387-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, P2RX5, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA3 4/4885 |
| US-20150157638-A1 | Methods for Treating Parkinson's Disease | ADORA2A, GRIN2A, GRIN3A | ADORA2A 1/4885ADORA1 6/4885ADORA3 8/4885 |
| US-20160367560-A1 | Methods for Treating Parkinson's Disease | ADORA2A, GRIN2A, GRIN3A | ADORA2A 1/4885ADORA1 6/4885ADORA3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.